Lewis, Karl D.
Larkin, James
Ribas, Antoni
Flaherty, Keith T.
McArthur, Grant A.
Ascierto, Paolo A.
Dréno, Brigitte
Yan, Yibing
Wongchenko, Matthew
McKenna, Edward
Zhu, Qian
Mun, Yong
Hauschild, Axel
Funding for this research was provided by:
F. Hoffmann-La Roche, Ltd.
Article History
Received: 26 November 2018
Revised: 22 July 2019
Accepted: 24 July 2019
First Online: 16 August 2019
Competing interests
: K.D.L. has received grants and personal fees from Roche/Genentech, and reports personal fees from Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, GlaxoSmithKline and Amgen. J.L. has been a consultant for Roche/Genentech, MSD, Novartis, Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb, and has received institutional research support from MSD, Novartis, Pfizer and Bristol-Myers Squibb. A.R. reports no conflicts of interest relevant to the submitted work. K.T.F. has been a consultant for and has received honoraria from Roche/Genentech. G.A.M. has been a consultant for and has been on advisory boards for Provectus, and has received research grants from Pfizer, Celgene and Ventana. P.A.A. has been a consultant or advisor for Amgen, Array, AstraZeneca, Bristol-Myers Squibb, Genmab, Incyte, Medimmune, Merck Serono, Merck Sharp & Dohme, Newlink Genetics, Novartis, Pierre Fabre, Roche/Genentech and Syndax; and has received research funding from BMS, Roche/Genentech and Array. B.D. has been a consultant or advisor for BMS, GlaxoSmithKline, Roche and Novartis; has served on speakers’ bureaus for BMS, GlaxoSmithKline and Roche; has received research funding from Amgen, BMS and GlaxoSmithKline; and has had travel accommodations and expenses paid for by BMS and Roche. Y.Y., M.W., E.M. and Y.M. are employees of and own stock in Roche-Genentech, Inc. Q.Z. is a consultant statistician for Roche-Genentech. A.H. has received clinical trial support from Amgen, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme, Novartis, Philogen, Pierre Fabre, Provectus, Regeneron and Roche and honoraria or consultancy fees from Amgen, Bristol-Myers Squibb, Merck Serono, MSD, Novartis, OncoSec, Philogen, Pierre Fabre, Provectus, Regeneron and Roche.
: Each trial was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical and Laboratory Practice and with the approval of appropriate ethics committees. All participants provided written informed consent.
: The work was supported by F. Hoffman-La Roche, Ltd.
: The authors declare that all data supporting the findings of this study are available within the article and its Supplementary Information files or are available from the corresponding author upon reasonable request.